Abstract: An object of the present invention is to expand CD34+ cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34+ cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells. A method for expanding CD34+ cells, which comprises culturing CD34+ cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L1, L2, L3, L4, R1, R2, R3, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof.

Abstract: An object of the present invention is to expand CD34+ cells ex vivo efficiently in a short term using a biologically safe and inexpensively obtainable low molecular weight compound. A still another object of the present invention is to provide an expansion agent for CD34+ cells useful for treatment of various hematopoietic disorders caused by dysfunctional hematopoietic stem cells and/or hematopoietic progenitor cells. A method for expanding CD34+ cells, which comprises culturing CD34+ cells ex vivo in the presence of a compound represented by the formula (I) (wherein A, B, L1, L2, L3, L4, R1, R2, R3, X and Y are defined in the description), a tautomer or pharmaceutically acceptable salt of the compound, or a solvate thereof.

Abstract: Disclosed is a compound having a strong affinity to serotonin-4 receptors, which is useful as an enterokinesis-promoting agent or a digestive tract function-improving agent. Specifically, disclosed is a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. Also specifically disclosed is a pharmaceutical composition containing a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. [In Formula (1), Ar represents a group represented by Formula (Ar-1) or Formula (Ar-2).

Abstract: A thermoelectric conversion module component includes a laminate formed of a plurality of stacked thermoelectric elements each including a unit circuit having repeated pn junction pairs that extend meanderingly and that are formed of p-type thermoelectric material layers and n-type thermoelectric material layers arranged so as to be alternately connected to each other on a surface of an insulating layer, and oblique joint surfaces at which electrodes are led out of the laminate. The oblique joint surfaces are such that a plurality of the thermoelectric conversion module components are electrically connected by contacting the surfaces with each other to form a ring. A thermoelectric conversion module includes a plurality of the thermoelectric conversion module components connected to each other to form a ring.

Abstract: A thermoelectric conversion element, a thermoelectric conversion module, and a method for producing a thermoelectric conversion element are provided, each of the element and the module having a low contact resistance between a p-type thermoelectric conversion material and an n-type thermoelectric conversion material and being capable of being used at high temperatures without deterioration due to oxidation. A p-type oxide thermoelectric conversion material is primarily made of a substance having a layered perovskite structure represented by the formula: A2BO4, wherein A includes at least La, and B represents at least one element including at least Cu. An n-type oxide thermoelectric conversion material is primarily made of a substance having a layered perovskite structure represented by the formula: D2EO4, wherein D includes at least one of Pr, Nd, Sm, and Gd, and E represents at least one element including at least Cu.

Abstract: A thermoelectric conversion module includes a laminated body including a plurality of thermoelectric components laminated therein. Each of the thermoelectric components includes an insulating layer, and a thermoelectric conversion element section in which a plurality of p-type thermoelectric conversion material layers and a plurality of n-type thermoelectric conversion material layers are arranged on the insulating layer in a series connection. A step eliminating insulating material layer is arranged to eliminate a step between the thermoelectric conversion element section and a vicinity thereof, in a region between the insulating layers adjacent to each other in a laminating direction, around the p-type thermoelectric conversion material layers and n-type thermoelectric conversion material layers constituting the thermoelectric conversion element section. The thermoelectric conversion element section has a serpentine shape.

Abstract: A hydraulic machine having a hydro turbine runner which has a crown at a center and a band along an outer periphery, and is formed around the axis of rotation, long blades which are arranged along the circumferential direction of the axis of rotation, and whose center-side ends are supported by the crown, and periphery-side ends are supported by the band, and short blades which are arranged between the long blades, and whose center-side ends are supported by the crown, periphery-side ends are supported by the band, and rear edges are curved in a rotation direction of the hydro turbine runner in turbine operation, on a plane of projection perpendicular to the axis of rotation.

Abstract: A p-type oxide thermoelectric material which has a high output factor and a low environmental load. The thermoelectric material is composed of an oxide represented by the compositional formula (Ni1-xCux) (Mn2-yCuy)O4 and having a structure in which Ni elements occupying the Ni sites and/or Mn elements occupying the Mn sites are partially replaced by Cu elements, wherein 0?x?0.7, 0?y?0.7, and 0.4?x+y. In such a thermoelectric material, preferably, 0.2?x?0.5 and 0.2?y?0.5, and preferably, the output factor at 50° C. to 800° C. is 10×10?6 W/mK2 or more.

Abstract: A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.

Abstract: Compounds effective for preventing, treatment or improving diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R1, R2, R3, L1, L2, L3, X and Y are defined in the description), a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Abstract: A p-type oxide thermoelectric material which has a high output factor and a low environmental load. The thermoelectric material is composed of an oxide represented by the compositional formula (Ni1-xCux) (Mn2-yCuy)O4 and having a structure in which Ni elements occupying the Ni sites and/or Mn elements occupying the Mn sites are partially replaced by Cu elements, wherein 0?x?0.7, 0?y?0.7, and 0.4?x+y. In such a thermoelectric material, preferably, 0.2?x?0.5 and 0.2?y?0.5, and preferably, the output factor at 50° C. to 800° C. is 10×10?6 W/mK2 or more.

Abstract: A compact, high-performance thermoelectric conversion module includes a laminate having a plurality of insulating layers, p-type thermoelectric semiconductors and n-type thermoelectric semiconductors formed by a technique for manufacturing a multilayer circuit board, particularly a technique for forming a via-conductor. Pairs of the p-type thermoelectric semiconductors and the n-type thermoelectric semiconductors are electrically connected to each other in series through p-n connection conductors to define thermoelectric conversion element pairs. The thermoelectric conversion element pairs are connected in series through, for example, series wiring conductors. The thermoelectric semiconductors each have a plurality of portions in which the peak temperatures of thermoelectric figures of merit are different from each other. These portions are distributed in the stacking direction of the laminate.

Abstract: By disclosing part of metastasis mechanisms in cancer cells, the metastatic potential of cancer cells will be determinable. Anti-galectin-9 Ab against galectin-9 is contained as an effective component with or without others, thereby enabling the evaluation or detection of galectin-9 expression levels in cancer cells wherein the metastatic potential of the cancer cells can be assessed or detected.

Abstract: A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13 SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Abstract: A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13, SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or is pharmaceutically acceptable salt of the compound or a solvate thereof.

Abstract: A Francis turbine with an improved shape of blades, which can reduce cavitations generated on the surface of the blades or reduce the secondary flow around the blades, is provided. A Francis turbine comprises a rotating shaft, a crown, a plurality of blades, and a band. The crown can rotate with the rotating shaft. The blades are circumferentially arranged on the crown, each of which including an inner end as a trailing edge. The band is coaxially coupled with the crown by the blades. The rotating shaft, the crown, the blades, and the band as a whole rotate toward a turbine direction during a turbine operation. A projected profile of the trailing edge on a perpendicular plane, which is perpendicular to a center axis of the rotating shaft, is curved toward a direction opposite to the turbine direction at least in the crown side.

Abstract: A Francis turbine with an improved shape of blades, which can reduce a circumferential velocity component generated in the flow downstream of the blades in a condition of a partial load operation, or reduce the secondary flow around the blades, is provided. A Francis turbine comprises a crown, a plurality of blades, and a band. The crown can rotate around a rotating axis. The blades are circumferentially arranged on the crown, each of which including an inner end as a trailing edge. The band is coaxially coupled with the crown by the blades. A distance Rc can be defined as a distance between the rotation axis and an end by the crown side of the trailing edge. A distance Rb can be defined as a distance between the rotation axis and an end by the band side of the trailing edge. The distance Rc and the distance Rb satisfy 0.2 ? R c R b ? 0.4 .

Abstract: The present invention provides an axial bolt force measuring instrument for measuring an axial force of a bolt for a hub that couples a wheel and an axle of a vehicle, where the instrument is provided with a setting portion that sets a predetermined axial force of the bolt, a tapping portion that taps the bolt, a sound collecting portion that collects tap sound generated by tapping the bolt with the tapping portion, a frequency measuring portion that measures a frequency of the tap sound collected by the sound collecting portion, an axial force converting portion that converts the frequency of the tap sound measured by the frequency measuring portion into an axial force of the bolt, a comparing portion that compares the set axial force set in the setting portion with the converted axial force converted in the axial force converting portion from the frequency of the tap sound, and a display portion that displays a result of comparison in the comparing portion.

Abstract: A compound represented by the formula (1): wherein A is a nitrogen atom or CR4, B is an oxygen atom, a sulfur atom or NR9 (provided that when A is a nitrogen atom, B is not NH), R1 is a C2-14 aryl group, L1 is a bond, CR10R11, an oxygen atom, a sulfur atom or NR12, X is OR13 SR13 or NR14NR15, R2 is a hydrogen atom, a formyl group, a C1-10 alkyl group or the like, L2 is a bond or the like, L3 is a bond, CR17R18, an oxygen atom, a sulfur atom or NR19, L4 is a bond, CR20R21, an oxygen atom, a sulfur atom or NR22, Y is an oxygen atom, a sulfur atom or NR23, and R3 is a C2-14 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the compound or a solvate thereof.

Abstract: A preventive, therapeutic or improving agent for diseases against which activation of the thrombopoietin receptor is effective or a platelet increasing agent, which contains a thrombopoietin receptor activator represented by the formula (1): wherein A is a C?2-14#191 aryl group, B is a hydrogen atom, a C?1-6#191 alkyl group, a C?1-3#191 alkyl group substituted with one or more fluorine atoms or a C?2-14#191 aryl group, D is a hydrogen atom, a C?1-6#191 alkyl group, a C?1-3#191 alkyl group substituted with one or more fluorine atoms or a C?2-14#191 aryl group, and E is a C?2-14#191 aryl group, a tautomer, prodrug or pharmaceutically acceptable salt of the activator or a solvate thereof, as an active ingredient.